Status:
COMPLETED
Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Covid 19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The RT-PCR on rhino-pharynge sampling highlights the genetic material of the virus and indicates that a subject is infected with SARS-CoV-2. This test can be in about 30% of false negative cases, it d...
Eligibility Criteria
Inclusion
- age ≥ 18 years,
- patients with confirmed SARS-Cov2 infection (RT PCR positive)
- or patients suspected (evocative chest scanner)
- OR patients exposure to SARS-CoV2 but no symptoms (patient's family, caregivers)
- OR patients Non exposure to SARS-Cov2 volunteer subjects (general population)
Exclusion
- pregnant or breastfeeding female
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 19 2022
Estimated Enrollment :
950 Patients enrolled
Trial Details
Trial ID
NCT04418206
Start Date
June 1 2020
End Date
July 19 2022
Last Update
October 25 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Antibes
Antibes, Alpes Maritimes, France, 06606
2
Ch Cannes, Pneumologie
Cannes, Alpes Maritimes, France, 06414
3
Ch Grasse
Grasse, Alpes Maritimes, France, 06355
4
CHU de nice
Nice, Alpes-Maritimes, France, 06001